Payment overview · 2025
General Payments
$263.87
17 reported records · 5 companies
Healthcare provider profile · identity verified
Mark R Crump, MD
Allopathic & Osteopathic Physicians|Family Medicine · CAMDEN, AR · NPI 1578530366
Verified facts
What the public records show
CMS Open Payments records show Mark R Crump, MD received $263.87 in general payments during 2025 across 17 reported records.
ABBVIE INC. accounted for 56.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Vraylar by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 223 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $148.58 | 56.3% | 11 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $48.26 | 18.3% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $30.82 | 11.7% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $19.86 | 7.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.35 | 6.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $263.87 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $115.88 | 7 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $115.88 | 7 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $48.26 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $32.70 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $30.82 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $30.82 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $19.86 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.35 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 223 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
223 | 39 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 954 | 172 |
| Atorvastatin Calcium | Atorvastatin Calcium | 935 | 182 |
| Gabapentin | Gabapentin | 768 | 140 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 660 | 103 |
| Pantoprazole Sodium | Pantoprazole Sodium | 611 | 129 |
| Furosemide | Furosemide | 552 | 115 |
| Potassium Chloride | Potassium Chloride | 503 | 110 |
| Amlodipine Besylate | Amlodipine Besylate | 491 | 99 |
| Metoprolol Tartrate | Metoprolol Tartrate | 409 | 81 |
| Losartan Potassium | Losartan Potassium | 384 | 74 |
| Omeprazole | Omeprazole | 369 | 83 |
| Meloxicam | Meloxicam | 346 | 75 |
| Metformin Hcl | Metformin Hcl | 317 | 63 |
| Glimepiride | Glimepiride | 311 | 64 |
| Tramadol Hcl | Tramadol Hcl | 310 | 77 |
| Metoprolol Succinate | Metoprolol Succinate | 307 | 64 |
| Tamsulosin Hcl | Tamsulosin Hcl | 279 | 61 |
| Lisinopril | Lisinopril | 268 | 60 |
| Carvedilol | Carvedilol | 262 | 51 |
| Diclofenac Sodium | Diclofenac Sodium | 257 | 84 |
| Allopurinol | Allopurinol | 255 | 53 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 252 | 72 |
| Buspirone Hcl | Buspirone Hcl | 250 | 53 |
| Simvastatin | Simvastatin | 248 | 59 |
| Zolpidem Tartrate | Zolpidem Tartrate | 248 | 48 |
| Trazodone Hcl | Trazodone Hcl | 238 | 57 |
| Clopidogrel | Clopidogrel Bisulfate | 228 | 43 |
| Eliquis | Apixaban | 223 | 39 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 222 | 48 |
| Benazepril Hcl | Benazepril Hcl | 219 | 45 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 216 | 49 |
| Citalopram Hbr | Citalopram Hydrobromide | 207 | 44 |
| Montelukast Sodium | Montelukast Sodium | 205 | 33 |
| Prednisone | Prednisone | 189 | 109 |
| Clonazepam | Clonazepam | 175 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 166 | 30 |
| Ozempic | Semaglutide | 166 | 30 |
| Alprazolam | Alprazolam | 163 | 30 |
| Bupropion Xl | Bupropion Hcl | 154 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 153 | 47 |
| Sertraline Hcl | Sertraline Hcl | 153 | 28 |
| Tizanidine Hcl | Tizanidine Hcl | 153 | 38 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 151 | 30 |
| Lorazepam | Lorazepam | 150 | 32 |
| Bumetanide | Bumetanide | 148 | 30 |
| Quetiapine Fumarate | Quetiapine Fumarate | 148 | 24 |
| Azithromycin | Azithromycin | 145 | 118 |
| Spironolactone | Spironolactone | 144 | 21 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 142 | 40 |
| Pregabalin | Pregabalin | 138 | 33 |
| Atenolol | Atenolol | 137 | 22 |
| Meclizine Hcl | Meclizine Hcl | 132 | 31 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 132 | 56 |
| Donepezil Hcl | Donepezil Hcl | 131 | 26 |
| Oxybutynin Chloride | Oxybutynin Chloride | 129 | 20 |
| Entresto | Sacubitril/Valsartan | 123 | 17 |
| Nabumetone | Nabumetone | 123 | 37 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 123 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 122 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 122 | 20 |
| Celecoxib | Celecoxib | 121 | 34 |
| Estradiol | Estradiol | 120 | 25 |
| Finasteride | Finasteride | 119 | 20 |
| Sucralfate | Sucralfate | 113 | 29 |
| Xarelto | Rivaroxaban | 111 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 106 | 17 |
| Mirtazapine | Mirtazapine | 104 | 26 |
| Fluoxetine Hcl | Fluoxetine Hcl | 103 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 100 | 24 |
| Ondansetron Odt | Ondansetron | 98 | 51 |
| Hydralazine Hcl | Hydralazine Hcl | 96 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 96 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 95 | 34 |
| Topiramate | Topiramate | 94 | 16 |
| Levofloxacin | Levofloxacin | 93 | 73 |
| Clonidine Hcl | Clonidine Hcl | 89 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 89 | 17 |
| Promethazine Hcl | Promethazine Hcl | 89 | 25 |
| Temazepam | Temazepam | 89 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 84 | 59 |
| Warfarin Sodium | Warfarin Sodium | 84 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 83 | suppressed |
| Fluconazole | Fluconazole | 83 | 32 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 81 | 24 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 81 | 14 |
| Levetiracetam | Levetiracetam | 77 | 13 |
| Ezetimibe | Ezetimibe | 76 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 75 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 74 | 24 |
| Amitriptyline Hcl | Amitriptyline Hcl | 73 | 16 |
| Cephalexin | Cephalexin | 73 | 54 |
| Hydrochlorothiazide | Hydrochlorothiazide | 71 | 18 |
| Mupirocin | Mupirocin | 71 | 38 |
| Nifedipine Er | Nifedipine | 68 | 12 |
| Sulindac | Sulindac | 68 | 16 |
| Fenofibrate | Fenofibrate Nanocrystallized | 66 | 13 |
| Nitroglycerin | Nitroglycerin | 62 | 19 |
| Pioglitazone Hcl | Pioglitazone Hcl | 62 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 59 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 59 | 17 |
| Doxazosin Mesylate | Doxazosin Mesylate | 57 | 15 |
| Latanoprost | Latanoprost | 57 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 57 | suppressed |
| Trulicity | Dulaglutide | 57 | 12 |
| Baclofen | Baclofen | 56 | suppressed |
| Lactulose | Lactulose | 56 | suppressed |
| Methylprednisolone | Methylprednisolone | 55 | 47 |
| Famotidine | Famotidine | 54 | 15 |
| Terbinafine Hcl | Terbinafine Hcl | 53 | 21 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 52 | 30 |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 52 | suppressed |
| Methocarbamol | Methocarbamol | 52 | 21 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 50 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 50 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 50 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 49 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 49 | 12 |
| Jardiance | Empagliflozin | 48 | suppressed |
| Methotrexate | Methotrexate Sodium | 48 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 48 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 47 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 47 | 13 |
| Risperidone | Risperidone | 47 | suppressed |
| Verapamil Er | Verapamil Hcl | 47 | 11 |
| Carisoprodol | Carisoprodol | 46 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 46 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 45 | 12 |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 45 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 44 | 26 |
| Mounjaro | Tirzepatide | 43 | suppressed |
| Aripiprazole | Aripiprazole | 41 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 41 | 21 |
| Naproxen | Naproxen | 40 | suppressed |
| Novolin R | Insulin Regular, Human | 40 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 39 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 37 | suppressed |
| Torsemide | Torsemide | 37 | suppressed |
| Valsartan | Valsartan | 37 | 11 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 36 | 16 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 36 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 36 | suppressed |
| Digoxin | Digoxin | 35 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 34 | suppressed |
| Ibuprofen | Ibuprofen | 34 | 18 |
| Ketoconazole | Ketoconazole | 34 | 16 |
| Synthroid | Levothyroxine Sodium | 34 | suppressed |
| Klor-Con M20 | Potassium Chloride | 33 | 11 |
| Humulin R | Insulin Regular, Human | 32 | suppressed |
| Diazepam | Diazepam | 31 | suppressed |
| Lamotrigine | Lamotrigine | 31 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 30 | 24 |
| Oxcarbazepine | Oxcarbazepine | 30 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 30 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 29 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 29 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 27 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 27 | suppressed |
| Olanzapine | Olanzapine | 27 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 27 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Acarbose | Acarbose | 25 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 25 | suppressed |
| Memantine Hcl | Memantine Hcl | 25 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 25 | 15 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 25 | suppressed |
| Hydrocortisone | Hydrocortisone | 24 | 16 |
| Indomethacin | Indomethacin | 24 | suppressed |
| Linzess | Linaclotide | 24 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Carbamazepine | Carbamazepine | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 22 | suppressed |
| Ranolazine Er | Ranolazine | 22 | suppressed |
| Nystatin | Nystatin | 21 | 12 |
| Raloxifene Hcl | Raloxifene Hcl | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 18 |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 20 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 20 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 20 | suppressed |
| Rexulti | Brexpiprazole | 20 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 19 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 18 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Vraylar | Cariprazine Hcl | 17 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 16 | suppressed |
| Lacosamide | Lacosamide | 16 | suppressed |
| Letrozole | Letrozole | 16 | suppressed |
| Metronidazole | Metronidazole | 16 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 16 | 13 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 15 | suppressed |
| Constulose | Lactulose | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Premarin | Estrogens, Conjugated | 15 | suppressed |
| Sulfasalazine | Sulfasalazine | 15 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 14 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Levemir | Insulin Detemir | 14 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 14 | suppressed |
| Phenobarbital | Phenobarbital | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Humalog | Insulin Lispro | 13 | suppressed |
| Klor-Con | Potassium Chloride | 13 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 13 | 13 |
| Primidone | Primidone | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Xifaxan | Rifaximin | 13 | suppressed |
| Zafemy | Norelgestromin/Ethin.Estradiol | 13 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 13 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Metaxalone | Metaxalone | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 12 | suppressed |
| Selegiline Hcl | Selegiline Hcl | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 12 | suppressed |
| Verapamil Sr | Verapamil Hcl | 12 | suppressed |
| Amiloride-Hydrochlorothiazide | Amiloride/Hydrochlorothiazide | 11 | suppressed |
| Anastrozole | Anastrozole | 11 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 11 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 11 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 11 | suppressed |
| Haloperidol | Haloperidol | 11 | suppressed |
| Methadone Hcl | Methadone Hcl | 11 | suppressed |
| Timolol Maleate | Timolol Maleate | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $263.87 · 17 records | ABBVIE INC. | CAPLYTA, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, NURTEC ODT, QULIPTA, UBRELVY, VRAYLAR | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error